TW201821080A - 用於治療發炎性疾病之化合物及其醫藥組合物 - Google Patents

Info

Publication number

TW201821080A

TW201821080A TW106139074A TW106139074A TW201821080A TW 201821080 A TW201821080 A TW 201821080A TW 106139074 A TW106139074 A TW 106139074A TW 106139074 A TW106139074 A TW 106139074A TW 201821080 A TW201821080 A TW 201821080A

Authority

TW

Taiwan

Prior art keywords

compound

treatment

pharmaceutically acceptable

acceptable salt

biomarker

Prior art date

2016-11-10

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 title claims abstract description 546
• 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 248
• 238000011282 treatment Methods 0.000 title claims abstract description 203
• 208000027866 inflammatory disease Diseases 0.000 title description 6
• 206010025135 lupus erythematosus Diseases 0.000 claims abstract description 110
• 208000005777 Lupus Nephritis Diseases 0.000 claims abstract description 95
• 208000004631 alopecia areata Diseases 0.000 claims abstract description 78
• 208000007465 Giant cell arteritis Diseases 0.000 claims abstract description 69
• 206010043207 temporal arteritis Diseases 0.000 claims abstract description 68
• 206010047642 Vitiligo Diseases 0.000 claims abstract description 9
• 239000003814 drug Substances 0.000 claims description 208
• 150000003839 salts Chemical class 0.000 claims description 202
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 160
• 201000010099 disease Diseases 0.000 claims description 151
• 230000002265 prevention Effects 0.000 claims description 109
• 239000000090 biomarker Substances 0.000 claims description 107
• 229940124597 therapeutic agent Drugs 0.000 claims description 105
• 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims description 97
• 239000003795 chemical substances by application Substances 0.000 claims description 58
• 206010027982 Morphoea Diseases 0.000 claims description 57
• 230000002829 reductive effect Effects 0.000 claims description 40
• 208000006926 Discoid Lupus Erythematosus Diseases 0.000 claims description 38
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 38
• 108090000623 proteins and genes Proteins 0.000 claims description 35
• 102000004169 proteins and genes Human genes 0.000 claims description 33
• -1 IFNγ Proteins 0.000 claims description 31
• 238000002203 pretreatment Methods 0.000 claims description 31
• 238000004519 manufacturing process Methods 0.000 claims description 30
• 230000000694 effects Effects 0.000 claims description 29
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 28
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 26
• 230000001684 chronic effect Effects 0.000 claims description 23
• 239000003937 drug carrier Substances 0.000 claims description 23
• 239000012453 solvate Substances 0.000 claims description 23
• 108090001005 Interleukin-6 Proteins 0.000 claims description 22
• 208000024891 symptom Diseases 0.000 claims description 22
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 21
• 108010036949 Cyclosporine Proteins 0.000 claims description 21
• 229960001265 ciclosporin Drugs 0.000 claims description 21
• 229930182912 cyclosporin Natural products 0.000 claims description 21
• 210000002700 urine Anatomy 0.000 claims description 21
• 229940109239 creatinine Drugs 0.000 claims description 20
• 210000004369 blood Anatomy 0.000 claims description 19
• 239000008280 blood Substances 0.000 claims description 19
• 229960000485 methotrexate Drugs 0.000 claims description 19
• 239000003246 corticosteroid Substances 0.000 claims description 18
• 229960002170 azathioprine Drugs 0.000 claims description 17
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 17
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 16
• 206010039491 Sarcoma Diseases 0.000 claims description 16
• 230000003115 biocidal effect Effects 0.000 claims description 16
• 229960004397 cyclophosphamide Drugs 0.000 claims description 16
• 230000006872 improvement Effects 0.000 claims description 16
• 239000002207 metabolite Substances 0.000 claims description 16
• 150000003431 steroids Chemical class 0.000 claims description 15
• 201000004384 Alopecia Diseases 0.000 claims description 14
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 13
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 13
• 239000003430 antimalarial agent Substances 0.000 claims description 13
• 230000008859 change Effects 0.000 claims description 13
• 239000003085 diluting agent Substances 0.000 claims description 13
• 201000001474 proteinuria Diseases 0.000 claims description 13
• 208000002193 Pain Diseases 0.000 claims description 12
• 229940125364 angiotensin receptor blocker Drugs 0.000 claims description 12
• 239000003242 anti bacterial agent Substances 0.000 claims description 12
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 12
• 206010003246 arthritis Diseases 0.000 claims description 11
• 210000003128 head Anatomy 0.000 claims description 11
• 229960004618 prednisone Drugs 0.000 claims description 11
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 11
• 230000002685 pulmonary effect Effects 0.000 claims description 11
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 10
• 239000002253 acid Substances 0.000 claims description 10
• 229960001334 corticosteroids Drugs 0.000 claims description 10
• 230000007423 decrease Effects 0.000 claims description 10
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 10
• 108010088751 Albumins Proteins 0.000 claims description 9
• 102000009027 Albumins Human genes 0.000 claims description 9
• 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims description 9
• 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims description 9
• 208000028656 Löfgren syndrome Diseases 0.000 claims description 9
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 9
• 229940046731 calcineurin inhibitors Drugs 0.000 claims description 9
• 230000003676 hair loss Effects 0.000 claims description 9
• 230000003681 hair reduction Effects 0.000 claims description 9
• 230000008929 regeneration Effects 0.000 claims description 9
• 238000011069 regeneration method Methods 0.000 claims description 9
• 229960004641 rituximab Drugs 0.000 claims description 9
• 201000003774 sarcomatosis Diseases 0.000 claims description 9
• 206010040882 skin lesion Diseases 0.000 claims description 9
• 231100000444 skin lesion Toxicity 0.000 claims description 9
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 8
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 8
• 238000004458 analytical method Methods 0.000 claims description 8
• 229940088710 antibiotic agent Drugs 0.000 claims description 8
• 210000004761 scalp Anatomy 0.000 claims description 8
• 206010037660 Pyrexia Diseases 0.000 claims description 7
• 230000001154 acute effect Effects 0.000 claims description 7
• 230000015572 biosynthetic process Effects 0.000 claims description 7
• 230000000747 cardiac effect Effects 0.000 claims description 7
• 206010016256 fatigue Diseases 0.000 claims description 7
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 7
• 102100036170 C-X-C motif chemokine 9 Human genes 0.000 claims description 6
• 229930186147 Cephalosporin Natural products 0.000 claims description 6
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 6
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 6
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 6
• 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 claims description 6
• 108090000174 Interleukin-10 Proteins 0.000 claims description 6
• OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 claims description 6
• 229930182555 Penicillin Natural products 0.000 claims description 6
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 6
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 6
• 229940124587 cephalosporin Drugs 0.000 claims description 6
• 150000001780 cephalosporins Chemical class 0.000 claims description 6
• WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims description 6
• 229960000598 infliximab Drugs 0.000 claims description 6
• 229960005287 lincomycin Drugs 0.000 claims description 6
• OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 claims description 6
• 239000003120 macrolide antibiotic agent Substances 0.000 claims description 6
• 229960001428 mercaptopurine Drugs 0.000 claims description 6
• XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 claims description 6
• 229940049954 penicillin Drugs 0.000 claims description 6
• 230000008961 swelling Effects 0.000 claims description 6
• 208000016261 weight loss Diseases 0.000 claims description 6
• 230000004580 weight loss Effects 0.000 claims description 6
• FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 claims description 5
• 206010011224 Cough Diseases 0.000 claims description 5
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 5
• 208000000059 Dyspnea Diseases 0.000 claims description 5
• 206010013975 Dyspnoeas Diseases 0.000 claims description 5
• 206010042674 Swelling Diseases 0.000 claims description 5
• 206010047513 Vision blurred Diseases 0.000 claims description 5
• 229960004171 hydroxychloroquine Drugs 0.000 claims description 5
• XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims description 5
• 230000001506 immunosuppresive effect Effects 0.000 claims description 5
• 210000003127 knee Anatomy 0.000 claims description 5
• 210000003141 lower extremity Anatomy 0.000 claims description 5
• 239000011976 maleic acid Substances 0.000 claims description 5
• 229960004023 minocycline Drugs 0.000 claims description 5
• 208000013220 shortness of breath Diseases 0.000 claims description 5
• 229940072172 tetracycline antibiotic Drugs 0.000 claims description 5
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 4
• 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 4
• 206010013774 Dry eye Diseases 0.000 claims description 4
• 206010018691 Granuloma Diseases 0.000 claims description 4
• 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 4
• 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 4
• 229960003697 abatacept Drugs 0.000 claims description 4
• 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 4
• 229940121363 anti-inflammatory agent Drugs 0.000 claims description 4
• 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 4
• 229940092714 benzenesulfonic acid Drugs 0.000 claims description 4
• 239000000969 carrier Substances 0.000 claims description 4
• 210000004027 cell Anatomy 0.000 claims description 4
• 210000003743 erythrocyte Anatomy 0.000 claims description 4
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims description 4
• 239000003550 marker Substances 0.000 claims description 4
• 229940098779 methanesulfonic acid Drugs 0.000 claims description 4
• KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 claims description 4
• 239000000049 pigment Substances 0.000 claims description 4
• 208000005069 pulmonary fibrosis Diseases 0.000 claims description 4
• 238000004062 sedimentation Methods 0.000 claims description 4
• 210000001364 upper extremity Anatomy 0.000 claims description 4
• 239000003981 vehicle Substances 0.000 claims description 4
• LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 claims description 3
• 238000009535 clinical urine test Methods 0.000 claims description 3
• 230000000295 complement effect Effects 0.000 claims description 3
• 208000024963 hair loss Diseases 0.000 claims description 3
• 208000029974 neurofibrosarcoma Diseases 0.000 claims description 3
• 235000006408 oxalic acid Nutrition 0.000 claims description 3
• 206010003230 arteritis Diseases 0.000 claims description 2
• 229960003270 belimumab Drugs 0.000 claims description 2
• 238000012360 testing method Methods 0.000 claims description 2
• SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 claims 1
• 241000448747 Clasis Species 0.000 claims 1
• 240000007594 Oryza sativa Species 0.000 claims 1
• 235000007164 Oryza sativa Nutrition 0.000 claims 1
• 229960003722 doxycycline Drugs 0.000 claims 1
• 201000002655 heart sarcoma Diseases 0.000 claims 1
• 201000010997 liver sarcoma Diseases 0.000 claims 1
• 201000003866 lung sarcoma Diseases 0.000 claims 1
• 235000009566 rice Nutrition 0.000 claims 1
• 238000000034 method Methods 0.000 abstract description 88
• 201000000306 sarcoidosis Diseases 0.000 abstract description 13
• 229940122245 Janus kinase inhibitor Drugs 0.000 abstract description 9
• 238000011321 prophylaxis Methods 0.000 abstract description 2
• 239000003112 inhibitor Substances 0.000 description 40
• 210000003491 skin Anatomy 0.000 description 40
• 229940079593 drug Drugs 0.000 description 37
• 239000000203 mixture Substances 0.000 description 32
• 235000018102 proteins Nutrition 0.000 description 28
• 229940068196 placebo Drugs 0.000 description 27
• 239000000902 placebo Substances 0.000 description 27
• 241000124008 Mammalia Species 0.000 description 26
• 102000015617 Janus Kinases Human genes 0.000 description 25
• 108010024121 Janus Kinases Proteins 0.000 description 25
• 102100038183 Tyrosine-protein kinase SYK Human genes 0.000 description 24
• 238000002560 therapeutic procedure Methods 0.000 description 23
• 108010000837 Janus Kinase 1 Proteins 0.000 description 21
• 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 21
• 229940125904 compound 1 Drugs 0.000 description 20
• 239000004480 active ingredient Substances 0.000 description 19
• 230000000699 topical effect Effects 0.000 description 18
• 102000004889 Interleukin-6 Human genes 0.000 description 17
• 230000003902 lesion Effects 0.000 description 16
• ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 16
• 208000011834 subacute cutaneous lupus erythematosus Diseases 0.000 description 16
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 16
• 241000519995 Stachys sylvatica Species 0.000 description 15
• 238000009472 formulation Methods 0.000 description 14
• 102000004127 Cytokines Human genes 0.000 description 13
• 108090000695 Cytokines Proteins 0.000 description 13
• 230000028327 secretion Effects 0.000 description 13
• 239000008024 pharmaceutical diluent Substances 0.000 description 12
• 238000012216 screening Methods 0.000 description 12
• 208000011830 chronic cutaneous lupus erythematosus Diseases 0.000 description 11
• 210000003734 kidney Anatomy 0.000 description 11
• 206010061218 Inflammation Diseases 0.000 description 10
• 230000004054 inflammatory process Effects 0.000 description 10
• 238000001126 phototherapy Methods 0.000 description 10
• 230000002485 urinary effect Effects 0.000 description 10
• 108010074051 C-Reactive Protein Proteins 0.000 description 9
• 102100032752 C-reactive protein Human genes 0.000 description 9
• 108010050904 Interferons Proteins 0.000 description 9
• 102000014150 Interferons Human genes 0.000 description 9
• 239000006071 cream Substances 0.000 description 9
• 208000017520 skin disease Diseases 0.000 description 9
• 230000009885 systemic effect Effects 0.000 description 9
• 239000003826 tablet Substances 0.000 description 9
• VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 8
• 230000009266 disease activity Effects 0.000 description 8
• 229940079322 interferon Drugs 0.000 description 8
• 239000007937 lozenge Substances 0.000 description 8
• 201000008383 nephritis Diseases 0.000 description 8
• 230000009467 reduction Effects 0.000 description 8
• 208000023275 Autoimmune disease Diseases 0.000 description 7
• 102000042838 JAK family Human genes 0.000 description 7
• 108091082332 JAK family Proteins 0.000 description 7
• HCIBTBXNLVOFER-UHFFFAOYSA-N diphenylcyclopropenone Chemical compound O=C1C(C=2C=CC=CC=2)=C1C1=CC=CC=C1 HCIBTBXNLVOFER-UHFFFAOYSA-N 0.000 description 7
• JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 7
• 230000002757 inflammatory effect Effects 0.000 description 7
• 210000004185 liver Anatomy 0.000 description 7
• 210000004379 membrane Anatomy 0.000 description 7
• 239000012528 membrane Substances 0.000 description 7
• 230000037361 pathway Effects 0.000 description 7
• 230000002062 proliferating effect Effects 0.000 description 7
• 239000000243 solution Substances 0.000 description 7
• 239000000126 substance Substances 0.000 description 7
• 230000001225 therapeutic effect Effects 0.000 description 7
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 6
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
• 108010074328 Interferon-gamma Proteins 0.000 description 6
• 102000013462 Interleukin-12 Human genes 0.000 description 6
• 108010065805 Interleukin-12 Proteins 0.000 description 6
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
• 230000006378 damage Effects 0.000 description 6
• 230000014509 gene expression Effects 0.000 description 6
• 230000005764 inhibitory process Effects 0.000 description 6
• 210000004072 lung Anatomy 0.000 description 6
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
• 230000001404 mediated effect Effects 0.000 description 6
• 239000002674 ointment Substances 0.000 description 6
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
• WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 5
• VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 5
• UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 5
• VOXBZHOHGGBLCQ-UHFFFAOYSA-N 2-amino-3,7-dihydropurine-6-thione;hydrate Chemical compound O.N1C(N)=NC(=S)C2=C1N=CN2.N1C(N)=NC(=S)C2=C1N=CN2 VOXBZHOHGGBLCQ-UHFFFAOYSA-N 0.000 description 5
• WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 5
• VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 5
• 229940123907 Disease modifying antirheumatic drug Drugs 0.000 description 5
• 108010008165 Etanercept Proteins 0.000 description 5
• 208000010201 Exanthema Diseases 0.000 description 5
• 241000282412 Homo Species 0.000 description 5
• 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 5
• 102000013264 Interleukin-23 Human genes 0.000 description 5
• 108010065637 Interleukin-23 Proteins 0.000 description 5
• 102000015696 Interleukins Human genes 0.000 description 5
• 108010063738 Interleukins Proteins 0.000 description 5
• 230000004163 JAK-STAT signaling pathway Effects 0.000 description 5
• UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 5
• FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 5
• 241000699670 Mus sp. Species 0.000 description 5
• 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 5
• 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 5
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 5
• 231100000360 alopecia Toxicity 0.000 description 5
• 229960004436 budesonide Drugs 0.000 description 5
• 229960003677 chloroquine Drugs 0.000 description 5
• 239000002988 disease modifying antirheumatic drug Substances 0.000 description 5
• 201000005884 exanthem Diseases 0.000 description 5
• 238000002474 experimental method Methods 0.000 description 5
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 5
• 230000000155 isotopic effect Effects 0.000 description 5
• 208000017169 kidney disease Diseases 0.000 description 5
• 229960004584 methylprednisolone Drugs 0.000 description 5
• HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 5
• STUHQDIOZQUPGP-UHFFFAOYSA-N morpholin-4-ium-4-carboxylate Chemical compound OC(=O)N1CCOCC1 STUHQDIOZQUPGP-UHFFFAOYSA-N 0.000 description 5
• 229940014456 mycophenolate Drugs 0.000 description 5
• HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 5
• 210000003739 neck Anatomy 0.000 description 5
• 210000000056 organ Anatomy 0.000 description 5
• 230000007170 pathology Effects 0.000 description 5
• 206010037844 rash Diseases 0.000 description 5
• 231100000241 scar Toxicity 0.000 description 5
• 230000037307 sensitive skin Effects 0.000 description 5
• 210000002966 serum Anatomy 0.000 description 5
• NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 5
• 229960001940 sulfasalazine Drugs 0.000 description 5
• NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 5
• 229960001967 tacrolimus Drugs 0.000 description 5
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 5
• 229960003433 thalidomide Drugs 0.000 description 5
• 229960003087 tioguanine Drugs 0.000 description 5
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
• 229940122739 Calcineurin inhibitor Drugs 0.000 description 4
• 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 description 4
• 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 description 4
• 208000032544 Cicatrix Diseases 0.000 description 4
• VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 4
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
• 108060003951 Immunoglobulin Proteins 0.000 description 4
• 102100020881 Interleukin-1 alpha Human genes 0.000 description 4
• 102000006503 Janus Kinase 2 Human genes 0.000 description 4
• 108010019437 Janus Kinase 2 Proteins 0.000 description 4
• 108010004729 Phycoerythrin Proteins 0.000 description 4
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 4
• 208000003251 Pruritus Diseases 0.000 description 4
• 108010044012 STAT1 Transcription Factor Proteins 0.000 description 4
• 102000006381 STAT1 Transcription Factor Human genes 0.000 description 4
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
• OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 4
• 210000003719 b-lymphocyte Anatomy 0.000 description 4
• 239000011324 bead Substances 0.000 description 4
• 229960000074 biopharmaceutical Drugs 0.000 description 4
• 229960002882 calcipotriol Drugs 0.000 description 4
• LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 4
• 239000002775 capsule Substances 0.000 description 4
• 230000003247 decreasing effect Effects 0.000 description 4
• 230000008021 deposition Effects 0.000 description 4
• VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 230000018109 developmental process Effects 0.000 description 4
• 229960003957 dexamethasone Drugs 0.000 description 4
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
• 238000003745 diagnosis Methods 0.000 description 4
• 208000035475 disorder Diseases 0.000 description 4
• 239000002552 dosage form Substances 0.000 description 4
• 229940073621 enbrel Drugs 0.000 description 4
• 210000001508 eye Anatomy 0.000 description 4
• 239000000796 flavoring agent Substances 0.000 description 4
• 229940043075 fluocinolone Drugs 0.000 description 4
• FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 4
• 235000013305 food Nutrition 0.000 description 4
• 230000001434 glomerular Effects 0.000 description 4
• 239000003862 glucocorticoid Substances 0.000 description 4
• 229940048921 humira Drugs 0.000 description 4
• 230000028993 immune response Effects 0.000 description 4
• 102000018358 immunoglobulin Human genes 0.000 description 4
• 229940072221 immunoglobulins Drugs 0.000 description 4
• 210000001503 joint Anatomy 0.000 description 4
• 210000001331 nose Anatomy 0.000 description 4
• 230000036961 partial effect Effects 0.000 description 4
• 230000002085 persistent effect Effects 0.000 description 4
• 239000000843 powder Substances 0.000 description 4
• 229960005205 prednisolone Drugs 0.000 description 4
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 4
• 108020003175 receptors Proteins 0.000 description 4
• 102000005962 receptors Human genes 0.000 description 4
• 230000001105 regulatory effect Effects 0.000 description 4
• 229940116176 remicade Drugs 0.000 description 4
• 230000004044 response Effects 0.000 description 4
• 230000037390 scarring Effects 0.000 description 4
• 230000037387 scars Effects 0.000 description 4
• 230000011664 signaling Effects 0.000 description 4
• 239000002904 solvent Substances 0.000 description 4
• 229960000565 tazarotene Drugs 0.000 description 4
• 230000008719 thickening Effects 0.000 description 4
• 229940035306 topicort Drugs 0.000 description 4
• QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 4
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
• 229930105110 Cyclosporin A Natural products 0.000 description 3
• YUXIBTJKHLUKBD-UHFFFAOYSA-N Dibutyl succinate Chemical compound CCCCOC(=O)CCC(=O)OCCCC YUXIBTJKHLUKBD-UHFFFAOYSA-N 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• 108010010803 Gelatin Proteins 0.000 description 3
• 102100037850 Interferon gamma Human genes 0.000 description 3
• 102000008070 Interferon-gamma Human genes 0.000 description 3
• 108010019421 Janus Kinase 3 Proteins 0.000 description 3
• 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
• 201000004681 Psoriasis Diseases 0.000 description 3
• 241000219061 Rheum Species 0.000 description 3
• 229920002472 Starch Polymers 0.000 description 3
• 108010010057 TYK2 Kinase Proteins 0.000 description 3
• FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 3
• 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 3
• 206010047115 Vasculitis Diseases 0.000 description 3
• 230000004913 activation Effects 0.000 description 3
• NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 description 3
• NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 3
• 229940092705 beclomethasone Drugs 0.000 description 3
• 239000011230 binding agent Substances 0.000 description 3
• 208000020832 chronic kidney disease Diseases 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 description 3
• 229960004287 clofazimine Drugs 0.000 description 3
• 230000006866 deterioration Effects 0.000 description 3
• 229960002097 dibutylsuccinate Drugs 0.000 description 3
• 229960002311 dithranol Drugs 0.000 description 3
• 150000002148 esters Chemical class 0.000 description 3
• 230000007717 exclusion Effects 0.000 description 3
• 235000013355 food flavoring agent Nutrition 0.000 description 3
• 229920000159 gelatin Polymers 0.000 description 3
• 239000008273 gelatin Substances 0.000 description 3
• 229940014259 gelatin Drugs 0.000 description 3
• 235000019322 gelatine Nutrition 0.000 description 3
• 235000011852 gelatine desserts Nutrition 0.000 description 3
• 230000024924 glomerular filtration Effects 0.000 description 3
• 150000002344 gold compounds Chemical class 0.000 description 3
• 208000006750 hematuria Diseases 0.000 description 3
• 150000004677 hydrates Chemical class 0.000 description 3
• 230000036039 immunity Effects 0.000 description 3
• 238000009169 immunotherapy Methods 0.000 description 3
• 208000015181 infectious disease Diseases 0.000 description 3
• 239000004615 ingredient Substances 0.000 description 3
• 238000002347 injection Methods 0.000 description 3
• 239000007924 injection Substances 0.000 description 3
• 208000014674 injury Diseases 0.000 description 3
• 229960003130 interferon gamma Drugs 0.000 description 3
• 229940047122 interleukins Drugs 0.000 description 3
• 230000003907 kidney function Effects 0.000 description 3
• 239000007788 liquid Substances 0.000 description 3
• 239000000314 lubricant Substances 0.000 description 3
• 235000019359 magnesium stearate Nutrition 0.000 description 3
• 230000003020 moisturizing effect Effects 0.000 description 3
• 230000008506 pathogenesis Effects 0.000 description 3
• 150000004492 retinoid derivatives Chemical class 0.000 description 3
• 206010039073 rheumatoid arthritis Diseases 0.000 description 3
• 230000001568 sexual effect Effects 0.000 description 3
• 239000007787 solid Substances 0.000 description 3
• XBRWELTXMQSEIN-UHFFFAOYSA-N squaric acid dibutyl ester Chemical compound CCCCOC1=C(OCCCC)C(=O)C1=O XBRWELTXMQSEIN-UHFFFAOYSA-N 0.000 description 3
• 239000008107 starch Substances 0.000 description 3
• 229940032147 starch Drugs 0.000 description 3
• 235000019698 starch Nutrition 0.000 description 3
• 239000012730 sustained-release form Substances 0.000 description 3
• 229940037128 systemic glucocorticoids Drugs 0.000 description 3
• 210000001519 tissue Anatomy 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 206010003694 Atrophy Diseases 0.000 description 2
• 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• 102000000018 Chemokine CCL2 Human genes 0.000 description 2
• 208000017667 Chronic Disease Diseases 0.000 description 2
• 208000011231 Crohn disease Diseases 0.000 description 2
• RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
• 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 2
• 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 2
• 206010020772 Hypertension Diseases 0.000 description 2
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
• 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 2
• 102000019223 Interleukin-1 receptor Human genes 0.000 description 2
• 108050006617 Interleukin-1 receptor Proteins 0.000 description 2
• 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 2
• 108050003558 Interleukin-17 Proteins 0.000 description 2
• 102000013691 Interleukin-17 Human genes 0.000 description 2
• 108010002350 Interleukin-2 Proteins 0.000 description 2
• 102000000588 Interleukin-2 Human genes 0.000 description 2
• 108090000978 Interleukin-4 Proteins 0.000 description 2
• 206010023232 Joint swelling Diseases 0.000 description 2
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
• 241000512015 Menetes Species 0.000 description 2
• BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
• 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 2
• 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 2
• 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 2
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
• 208000034189 Sclerosis Diseases 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
• 208000004732 Systemic Vasculitis Diseases 0.000 description 2
• 210000001744 T-lymphocyte Anatomy 0.000 description 2
• 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 2
• 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 2
• 241000212749 Zesius chrysomallus Species 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 230000002411 adverse Effects 0.000 description 2
• WUOACPNHFRMFPN-UHFFFAOYSA-N alpha-terpineol Chemical compound CC1=CCC(C(C)(C)O)CC1 WUOACPNHFRMFPN-UHFFFAOYSA-N 0.000 description 2
• 208000007502 anemia Diseases 0.000 description 2
• 210000001367 artery Anatomy 0.000 description 2
• 230000037444 atrophy Effects 0.000 description 2
• 239000002585 base Substances 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• 210000000845 cartilage Anatomy 0.000 description 2
• 150000001768 cations Chemical class 0.000 description 2
• 238000011260 co-administration Methods 0.000 description 2
• 239000003086 colorant Substances 0.000 description 2
• JBDSSBMEKXHSJF-UHFFFAOYSA-N cyclopentanecarboxylic acid Chemical compound OC(=O)C1CCCC1 JBDSSBMEKXHSJF-UHFFFAOYSA-N 0.000 description 2
• SQIFACVGCPWBQZ-UHFFFAOYSA-N delta-terpineol Natural products CC(C)(O)C1CCC(=C)CC1 SQIFACVGCPWBQZ-UHFFFAOYSA-N 0.000 description 2
• 230000035614 depigmentation Effects 0.000 description 2
• 230000000779 depleting effect Effects 0.000 description 2
• 238000001514 detection method Methods 0.000 description 2
• 239000012895 dilution Substances 0.000 description 2
• 238000010790 dilution Methods 0.000 description 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
• 238000009826 distribution Methods 0.000 description 2
• 201000004997 drug-induced lupus erythematosus Diseases 0.000 description 2
• 229940050411 fumarate Drugs 0.000 description 2
• 125000000524 functional group Chemical group 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
• 239000010931 gold Substances 0.000 description 2
• 229910052737 gold Inorganic materials 0.000 description 2
• 229960000890 hydrocortisone Drugs 0.000 description 2
• 206010020718 hyperplasia Diseases 0.000 description 2
• 239000003018 immunosuppressive agent Substances 0.000 description 2
• 229940125721 immunosuppressive agent Drugs 0.000 description 2
• 230000002458 infectious effect Effects 0.000 description 2
• 230000008595 infiltration Effects 0.000 description 2
• 238000001764 infiltration Methods 0.000 description 2
• 239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 2
• 108010074108 interleukin-21 Proteins 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• 230000002045 lasting effect Effects 0.000 description 2
• 210000002414 leg Anatomy 0.000 description 2
• 239000003446 ligand Substances 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• 210000004698 lymphocyte Anatomy 0.000 description 2
• 210000002540 macrophage Anatomy 0.000 description 2
• 239000011777 magnesium Substances 0.000 description 2
• 229910052749 magnesium Inorganic materials 0.000 description 2
• 201000004792 malaria Diseases 0.000 description 2
• 239000000463 material Substances 0.000 description 2
• 201000008350 membranous glomerulonephritis Diseases 0.000 description 2
• LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
• 239000008108 microcrystalline cellulose Substances 0.000 description 2
• 229940016286 microcrystalline cellulose Drugs 0.000 description 2
• 150000007522 mineralic acids Chemical class 0.000 description 2
• TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical compound OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
• 210000004400 mucous membrane Anatomy 0.000 description 2
• 210000000653 nervous system Anatomy 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• 230000026731 phosphorylation Effects 0.000 description 2
• 238000006366 phosphorylation reaction Methods 0.000 description 2
• 229910052700 potassium Inorganic materials 0.000 description 2
• 239000011591 potassium Substances 0.000 description 2
• 238000002360 preparation method Methods 0.000 description 2
• 230000000750 progressive effect Effects 0.000 description 2
• 230000000770 proinflammatory effect Effects 0.000 description 2
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
• 230000010346 psychosocial stress Effects 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
• 230000019491 signal transduction Effects 0.000 description 2
• 231100000046 skin rash Toxicity 0.000 description 2
• 201000004477 skin sarcoma Diseases 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 230000010097 squamous lesion Effects 0.000 description 2
• 230000000087 stabilizing effect Effects 0.000 description 2
• 238000003756 stirring Methods 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 239000011593 sulfur Substances 0.000 description 2
• 229910052717 sulfur Inorganic materials 0.000 description 2
• 230000036561 sun exposure Effects 0.000 description 2
• 238000013268 sustained release Methods 0.000 description 2
• 208000011580 syndromic disease Diseases 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• 230000002194 synthesizing effect Effects 0.000 description 2
• 238000009121 systemic therapy Methods 0.000 description 2
• 229940116411 terpineol Drugs 0.000 description 2
• IAQRGUVFOMOMEM-ONEGZZNKSA-N trans-but-2-ene Chemical compound C\C=C\C IAQRGUVFOMOMEM-ONEGZZNKSA-N 0.000 description 2
• 230000008733 trauma Effects 0.000 description 2
• 238000011269 treatment regimen Methods 0.000 description 2
• 102000003390 tumor necrosis factor Human genes 0.000 description 2
• QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
• LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
• KWMLJOLKUYYJFJ-GASJEMHNSA-N (2xi)-D-gluco-heptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C(O)=O KWMLJOLKUYYJFJ-GASJEMHNSA-N 0.000 description 1
• MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
• WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
• VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical compound CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
• AMMPLVWPWSYRDR-UHFFFAOYSA-N 1-methylbicyclo[2.2.2]oct-2-ene-4-carboxylic acid Chemical compound C1CC2(C(O)=O)CCC1(C)C=C2 AMMPLVWPWSYRDR-UHFFFAOYSA-N 0.000 description 1
• UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• KGUHUVQIJHGHLX-UHFFFAOYSA-N 2h-triazolo[4,5-b]pyridin-5-amine Chemical compound NC1=CC=C2NN=NC2=N1 KGUHUVQIJHGHLX-UHFFFAOYSA-N 0.000 description 1
• MLMQPDHYNJCQAO-UHFFFAOYSA-N 3,3-dimethylbutyric acid Chemical compound CC(C)(C)CC(O)=O MLMQPDHYNJCQAO-UHFFFAOYSA-N 0.000 description 1
• OJDZHBWEGLIKRW-UHFFFAOYSA-N 3-[(4-hydroxyphenyl)methyl]benzoic acid Chemical compound OC(=O)C1=CC=CC(CC=2C=CC(O)=CC=2)=C1 OJDZHBWEGLIKRW-UHFFFAOYSA-N 0.000 description 1
• RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
• HEUHSLIQDPUGEK-UHFFFAOYSA-N 5-phenyl-[1,2,4]triazolo[1,5-a]pyridine-2-carboxamide Chemical class N12N=C(C(=O)N)N=C2C=CC=C1C1=CC=CC=C1 HEUHSLIQDPUGEK-UHFFFAOYSA-N 0.000 description 1
• 206010063409 Acarodermatitis Diseases 0.000 description 1
• 244000058084 Aegle marmelos Species 0.000 description 1
• 235000003930 Aegle marmelos Nutrition 0.000 description 1
• 241000936955 Alepocephalidae Species 0.000 description 1
• 208000019901 Anxiety disease Diseases 0.000 description 1
• 208000006820 Arthralgia Diseases 0.000 description 1
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• 201000004569 Blindness Diseases 0.000 description 1
• 108700012434 CCL3 Proteins 0.000 description 1
• 229940124292 CD20 monoclonal antibody Drugs 0.000 description 1
• BQENDLAVTKRQMS-SBBGFIFASA-L Carbenoxolone sodium Chemical compound [Na+].[Na+].C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)CCC([O-])=O)C1(C)C BQENDLAVTKRQMS-SBBGFIFASA-L 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
• OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
• 208000024172 Cardiovascular disease Diseases 0.000 description 1
• 206010007764 Cataract subcapsular Diseases 0.000 description 1
• 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
• 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
• 206010007882 Cellulitis Diseases 0.000 description 1
• 102000000013 Chemokine CCL3 Human genes 0.000 description 1
• 102000001326 Chemokine CCL4 Human genes 0.000 description 1
• 108010055165 Chemokine CCL4 Proteins 0.000 description 1
• 229920001268 Cholestyramine Polymers 0.000 description 1
• 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
• 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
• WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
• 206010010356 Congenital anomaly Diseases 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
• RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
• 201000004624 Dermatitis Diseases 0.000 description 1
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 208000017701 Endocrine disease Diseases 0.000 description 1
• 206010015150 Erythema Diseases 0.000 description 1
• 208000001034 Frostbite Diseases 0.000 description 1
• 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
• 206010060891 General symptom Diseases 0.000 description 1
• 206010018364 Glomerulonephritis Diseases 0.000 description 1
• 206010018372 Glomerulonephritis membranous Diseases 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 206010019233 Headaches Diseases 0.000 description 1
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
• 102000001554 Hemoglobins Human genes 0.000 description 1
• 108010054147 Hemoglobins Proteins 0.000 description 1
• 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
• 101000665442 Homo sapiens Serine/threonine-protein kinase TBK1 Proteins 0.000 description 1
• 208000035150 Hypercholesterolemia Diseases 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 230000005353 IP-10 production Effects 0.000 description 1
• 206010061598 Immunodeficiency Diseases 0.000 description 1
• 208000029462 Immunodeficiency disease Diseases 0.000 description 1
• 206010062016 Immunosuppression Diseases 0.000 description 1
• 102000000589 Interleukin-1 Human genes 0.000 description 1
• 108010002352 Interleukin-1 Proteins 0.000 description 1
• 102000003816 Interleukin-13 Human genes 0.000 description 1
• 108090000176 Interleukin-13 Proteins 0.000 description 1
• 108090000172 Interleukin-15 Proteins 0.000 description 1
• 102100030703 Interleukin-22 Human genes 0.000 description 1
• 108010002616 Interleukin-5 Proteins 0.000 description 1
• 108010002586 Interleukin-7 Proteins 0.000 description 1
• 108090001007 Interleukin-8 Proteins 0.000 description 1
• 108010002335 Interleukin-9 Proteins 0.000 description 1
• 206010022562 Intermittent claudication Diseases 0.000 description 1
• 102000008986 Janus Human genes 0.000 description 1
• 108050000950 Janus Proteins 0.000 description 1
• 229940116839 Janus kinase 1 inhibitor Drugs 0.000 description 1
• 229940121730 Janus kinase 2 inhibitor Drugs 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 102100032352 Leukemia inhibitory factor Human genes 0.000 description 1
• 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
• 208000019693 Lung disease Diseases 0.000 description 1
• 206010050551 Lupus-like syndrome Diseases 0.000 description 1
• 235000006679 Mentha X verticillata Nutrition 0.000 description 1
• 235000002899 Mentha suaveolens Nutrition 0.000 description 1
• 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
• 241001465754 Metazoa Species 0.000 description 1
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
• 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 1
• 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 1
• 239000004909 Moisturizer Substances 0.000 description 1
• TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Natural products OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• 239000006057 Non-nutritive feed additive Substances 0.000 description 1
• 108090000630 Oncostatin M Proteins 0.000 description 1
• 102100031942 Oncostatin-M Human genes 0.000 description 1
• 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
• 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
• 229910052778 Plutonium Inorganic materials 0.000 description 1
• 208000010378 Pulmonary Embolism Diseases 0.000 description 1
• LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
• 206010037868 Rash maculo-papular Diseases 0.000 description 1
• 206010038548 Renal vein thrombosis Diseases 0.000 description 1
• 102000007078 STAT Transcription Factors Human genes 0.000 description 1
• 108010072819 STAT Transcription Factors Proteins 0.000 description 1
• 241000124033 Salix Species 0.000 description 1
• 241000447727 Scabies Species 0.000 description 1
• 229940124639 Selective inhibitor Drugs 0.000 description 1
• 102100038192 Serine/threonine-protein kinase TBK1 Human genes 0.000 description 1
• 101710140204 Signal transducer and transcription activator Proteins 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• 208000021386 Sjogren Syndrome Diseases 0.000 description 1
• 206010040943 Skin Ulcer Diseases 0.000 description 1
• 206010040860 Skin haemorrhages Diseases 0.000 description 1
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 108010090804 Streptavidin Proteins 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• 206010042496 Sunburn Diseases 0.000 description 1
• 230000024932 T cell mediated immunity Effects 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• 210000000447 Th1 cell Anatomy 0.000 description 1
• 208000007536 Thrombosis Diseases 0.000 description 1
• 208000024799 Thyroid disease Diseases 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 206010052779 Transplant rejections Diseases 0.000 description 1
• GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
• 208000025865 Ulcer Diseases 0.000 description 1
• 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• 101001001642 Xenopus laevis Serine/threonine-protein kinase pim-3 Proteins 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 229960001138 acetylsalicylic acid Drugs 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 206010000496 acne Diseases 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000011149 active material Substances 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 229960002964 adalimumab Drugs 0.000 description 1
• 210000000577 adipose tissue Anatomy 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 238000009098 adjuvant therapy Methods 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 229910001413 alkali metal ion Inorganic materials 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• 239000012491 analyte Substances 0.000 description 1
• ATUINOWSBQKFKB-UHFFFAOYSA-N anthracene phenol Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C12.C1(=CC=CC=C1)O ATUINOWSBQKFKB-UHFFFAOYSA-N 0.000 description 1
• 230000036506 anxiety Effects 0.000 description 1
• 230000004596 appetite loss Effects 0.000 description 1
• 239000012736 aqueous medium Substances 0.000 description 1
• 239000008135 aqueous vehicle Substances 0.000 description 1
• 239000010426 asphalt Substances 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 230000002146 bilateral effect Effects 0.000 description 1
• 238000012742 biochemical analysis Methods 0.000 description 1
• 239000003124 biologic agent Substances 0.000 description 1
• 239000013060 biological fluid Substances 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
• 201000009267 bronchiectasis Diseases 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• IAQRGUVFOMOMEM-UHFFFAOYSA-N butene Natural products CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 238000011088 calibration curve Methods 0.000 description 1
• 210000001736 capillary Anatomy 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 210000000269 carotid artery external Anatomy 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 208000037976 chronic inflammation Diseases 0.000 description 1
• 230000006020 chronic inflammation Effects 0.000 description 1
• 235000013985 cinnamic acid Nutrition 0.000 description 1
• 229930016911 cinnamic acid Natural products 0.000 description 1
• 235000015165 citric acid Nutrition 0.000 description 1
• 208000024980 claudication Diseases 0.000 description 1
• 239000008119 colloidal silica Substances 0.000 description 1
• 229940000425 combination drug Drugs 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 238000011461 current therapy Methods 0.000 description 1
• YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
• 229940127089 cytotoxic agent Drugs 0.000 description 1
• 239000002254 cytotoxic agent Substances 0.000 description 1
• 231100000599 cytotoxic agent Toxicity 0.000 description 1
• 238000013480 data collection Methods 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 238000011257 definitive treatment Methods 0.000 description 1
• 230000003412 degenerative effect Effects 0.000 description 1
• 238000006356 dehydrogenation reaction Methods 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 231100000223 dermal penetration Toxicity 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 229910052805 deuterium Inorganic materials 0.000 description 1
• 229960002086 dextran Drugs 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 238000000502 dialysis Methods 0.000 description 1
• 150000004985 diamines Chemical class 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• 229940105990 diglycerin Drugs 0.000 description 1
• GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 239000012636 effector Substances 0.000 description 1
• 201000000523 end stage renal failure Diseases 0.000 description 1
• 230000002124 endocrine Effects 0.000 description 1
• 210000003038 endothelium Anatomy 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 231100000321 erythema Toxicity 0.000 description 1
• 229960000403 etanercept Drugs 0.000 description 1
• AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
• 230000004090 etiopathogenesis Effects 0.000 description 1
• 238000010195 expression analysis Methods 0.000 description 1
• 210000003414 extremity Anatomy 0.000 description 1
• 208000030533 eye disease Diseases 0.000 description 1
• 230000001815 facial effect Effects 0.000 description 1
• 239000003269 fluorescent indicator Substances 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 235000011087 fumaric acid Nutrition 0.000 description 1
• 230000006870 function Effects 0.000 description 1
• ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
• 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
• 210000005086 glomerual capillary Anatomy 0.000 description 1
• 210000003904 glomerular cell Anatomy 0.000 description 1
• 206010061989 glomerulosclerosis Diseases 0.000 description 1
• 239000000174 gluconic acid Substances 0.000 description 1
• 235000012208 gluconic acid Nutrition 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 235000011187 glycerol Nutrition 0.000 description 1
• 210000004013 groin Anatomy 0.000 description 1
• 208000035474 group of disease Diseases 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 230000003660 hair regeneration Effects 0.000 description 1
• 231100000869 headache Toxicity 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 210000002216 heart Anatomy 0.000 description 1
• 230000009033 hematopoietic malignancy Effects 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 239000008309 hydrophilic cream Substances 0.000 description 1
• 230000005934 immune activation Effects 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 230000007813 immunodeficiency Effects 0.000 description 1
• 230000007365 immunoregulation Effects 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 239000012678 infectious agent Substances 0.000 description 1
• 210000004969 inflammatory cell Anatomy 0.000 description 1
• 230000004968 inflammatory condition Effects 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 230000010354 integration Effects 0.000 description 1
• 229940047124 interferons Drugs 0.000 description 1
• 239000000543 intermediate Substances 0.000 description 1
• 230000031146 intracellular signal transduction Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 229940045996 isethionic acid Drugs 0.000 description 1
• FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
• 210000002510 keratinocyte Anatomy 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 208000030175 lameness Diseases 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 239000006193 liquid solution Substances 0.000 description 1
• 239000006194 liquid suspension Substances 0.000 description 1
• 208000019017 loss of appetite Diseases 0.000 description 1
• 235000021266 loss of appetite Nutrition 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 239000003055 low molecular weight heparin Substances 0.000 description 1
• 229940127215 low-molecular weight heparin Drugs 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 239000001630 malic acid Substances 0.000 description 1
• 235000011090 malic acid Nutrition 0.000 description 1
• 238000007726 management method Methods 0.000 description 1
• 229960002510 mandelic acid Drugs 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 238000013160 medical therapy Methods 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• 201000001441 melanoma Diseases 0.000 description 1
• 108020004084 membrane receptors Proteins 0.000 description 1
• 102000006240 membrane receptors Human genes 0.000 description 1
• 231100000855 membranous nephropathy Toxicity 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 229910021645 metal ion Inorganic materials 0.000 description 1
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
• 229960002216 methylparaben Drugs 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 230000001333 moisturizer Effects 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 210000004877 mucosa Anatomy 0.000 description 1
• 210000004165 myocardium Anatomy 0.000 description 1
• GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
• 208000026721 nail disease Diseases 0.000 description 1
• 208000004235 neutropenia Diseases 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 206010029410 night sweats Diseases 0.000 description 1
• 230000036565 night sweats Effects 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 239000002687 nonaqueous vehicle Substances 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 239000003883 ointment base Substances 0.000 description 1
• 229940124624 oral corticosteroid Drugs 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 206010033675 panniculitis Diseases 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 210000003695 paranasal sinus Anatomy 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 230000007310 pathophysiology Effects 0.000 description 1
• 230000000149 penetrating effect Effects 0.000 description 1
• 229960001639 penicillamine Drugs 0.000 description 1
• 210000005259 peripheral blood Anatomy 0.000 description 1
• 239000011886 peripheral blood Substances 0.000 description 1
• 235000019271 petrolatum Nutrition 0.000 description 1
• 229940124531 pharmaceutical excipient Drugs 0.000 description 1
• 239000002831 pharmacologic agent Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 239000002953 phosphate buffered saline Substances 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• 210000004694 pigment cell Anatomy 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
• OYEHPCDNVJXUIW-UHFFFAOYSA-N plutonium atom Chemical compound [Pu] OYEHPCDNVJXUIW-UHFFFAOYSA-N 0.000 description 1
• 238000002600 positron emission tomography Methods 0.000 description 1
• 230000003449 preventive effect Effects 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 230000008741 proinflammatory signaling process Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 235000019260 propionic acid Nutrition 0.000 description 1
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• ODLMAHJVESYWTB-UHFFFAOYSA-N propylbenzene Chemical compound CCCC1=CC=CC=C1 ODLMAHJVESYWTB-UHFFFAOYSA-N 0.000 description 1
• 229960003415 propylparaben Drugs 0.000 description 1
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 239000003087 receptor blocking agent Substances 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 230000001172 regenerating effect Effects 0.000 description 1
• 230000029058 respiratory gaseous exchange Effects 0.000 description 1
• 210000002345 respiratory system Anatomy 0.000 description 1
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
• 229940081974 saccharin Drugs 0.000 description 1
• 235000019204 saccharin Nutrition 0.000 description 1
• 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
• 229960004889 salicylic acid Drugs 0.000 description 1
• 208000005687 scabies Diseases 0.000 description 1
• 239000013049 sediment Substances 0.000 description 1
• 239000012748 slip agent Substances 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
• 239000004299 sodium benzoate Substances 0.000 description 1
• 235000010234 sodium benzoate Nutrition 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
• 239000008109 sodium starch glycolate Substances 0.000 description 1
• 229940079832 sodium starch glycolate Drugs 0.000 description 1
• 229920003109 sodium starch glycolate Polymers 0.000 description 1
• 239000008247 solid mixture Substances 0.000 description 1
• 238000003797 solvolysis reaction Methods 0.000 description 1
• 230000007480 spreading Effects 0.000 description 1
• 238000003892 spreading Methods 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 210000004304 subcutaneous tissue Anatomy 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 229960005349 sulfur Drugs 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 238000002626 targeted therapy Methods 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• 125000005207 tetraalkylammonium group Chemical group 0.000 description 1
• 229960002180 tetracycline Drugs 0.000 description 1
• 229930101283 tetracycline Natural products 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• 206010043554 thrombocytopenia Diseases 0.000 description 1
• 230000001732 thrombotic effect Effects 0.000 description 1
• 208000021510 thyroid gland disease Diseases 0.000 description 1
• 229960004247 tofacitinib citrate Drugs 0.000 description 1
• SYIKUFDOYJFGBQ-YLAFAASESA-N tofacitinib citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 SYIKUFDOYJFGBQ-YLAFAASESA-N 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 239000003860 topical agent Substances 0.000 description 1
• 229940100611 topical cream Drugs 0.000 description 1
• 229940100615 topical ointment Drugs 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 229960005486 vaccine Drugs 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 210000005167 vascular cell Anatomy 0.000 description 1
• 210000001835 viscera Anatomy 0.000 description 1
• 239000003871 white petrolatum Substances 0.000 description 1